Biotech Took the Week. The Rest of the IPO Calendar Still Had Work to Do.

The week of April 27 to May 3 finally turned IPO optimism into executed biotech paper. After X-Energy filed its final prospectus for a $1.02 billion IPO and jumped 30.9% in its April 24 debut, according to Reuters, the market spent this review week showing that demand was not limited to one AI-power trade. Avalyn Pharma priced 16.67 million shares at $18 for $300 million, then closed its first session at $29.49; by May 1, the company said underwriters had fully exercised the 2.5 million-share option. Hemab and Seaport followed with top-of-range, upsized pricings that made the week feel like a real reopening instead of another burst of amended paperwork.

Biotech was where execution improved

Hemab Therapeutics sold 16.75 million shares at $18, raising $301.5 million after entering the week seeking roughly $212 million, and its own pricing release confirmed trading would begin on May 1. That debut was emphatic: Bloomberg Law reported the stock closed at $34, up 89%. Seaport was almost as clean. Its final prospectus shows 14.16 million shares priced at $18 for $254.9 million, up from the 11.8 million shares initially marketed, with Bloomberg and the filing both pointing to top-of-range demand. The same prospectus also disclosed a $50 million indication of interest from General Atlantic. On day one, Seaport closed at $19.84, a solid but less euphoric handoff than Hemab or Avalyn.

That cluster matters more than any single debut pop. In two sessions, investors absorbed roughly $856 million of gross biotech IPO issuance across Avalyn, Hemab, and Seaport, with Morgan Stanley, Goldman Sachs, Jefferies, J.P. Morgan, Evercore ISI, Leerink, and Citigroup spread across the books. The common thread was straightforward: clinical-stage risk was acceptable when paired with large syndicates, clean primary issuance, and visible development catalysts. That is a narrower reopening than a broad risk-on tape, but it is a reopening.

Outside biotech, progress was real but less conclusive

HawkEye 360 kept the non-biotech side of the calendar interesting, but not yet proven. The company said in its roadshow launch release and latest S-1/A that it was marketing 16 million shares at $24 to $26, implying up to roughly $416 million of proceeds. Reuters reported that range valued the RF intelligence company at as much as $2.42 billion. The setup was credible: government-heavy revenue, a national-security lane investors understand, and a Goldman-Morgan Stanley-led book. But the deal had not priced by week-end, so the market had not yet validated that valuation.

Suja Life also launched, but with a structure that asks investors to underwrite more than beverage growth. In its IPO launch release, the company set out an 8.89 million-share offering at $21 to $24, while its amended filing kept the Up-C and balance-sheet cleanup front and center. Proceeds were set to flow into LP unit purchases and debt repayment rather than a simple growth-capital story. That does not kill a deal, but it raises the bar in a market that just showed a preference for cleaner biotech financings.

Silver Bow Mining did get across the line, and the terms told their own story. The company said in its pricing release that it sold 5.2 million shares at $11.50 for $59.8 million. Renaissance Capital noted that Silver Bow increased the share count but cut the range from an earlier $12 to $15 filing to $10 to $13 before pricing at the midpoint. That is still a successful financing. It is just not the same quality of demand signal as the week’s biotech prints.

What still looked unresolved

The backlog is there, but investors are still choosing carefully. Rare Earths Americas launched a $17 to $19 deal for up to $52.8 million, according to Reuters, showing that critical-minerals scarcity still travels as an IPO theme. GMR Solutions, meanwhile, remained more a candidate than a transaction. Its April filing put $5.74 billion of 2025 revenue and $206.2 million of net income in front of investors, but by the end of this week the company was still in filing mode, not pricing mode.

The week mattered because it separated calendar breadth from true execution. Biotech not only priced; it upsized, priced at the top, and traded well enough to confirm that institutional demand is back for the right names. Outside that lane, the calendar continued to move, but usually with more negotiation around valuation, structure, or both. For IPO readers, that is the clean takeaway: the window is open, but it is not open evenly.